Abstract
The amino-acid-derived polyamines have long been associated with cell growth and cancer, and specific oncogenes and tumour-suppressor genes regulate polyamine metabolism. Inhibition of polyamine synthesis has proven to be generally ineffective as an anticancer strategy in clinical trials, but it is a potent cancer chemoprevention strategy in preclinical studies. Clinical trials, with well-defined goals, are now underway to evaluate the chemopreventive efficacy of inhibitors of polyamine synthesis in a range of tissues.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Anti-Inflammatory Agents, Non-Steroidal / pharmacology
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use
-
Chemoprevention
-
Colorectal Neoplasms / prevention & control
-
Cyclooxygenase 2
-
Cyclooxygenase 2 Inhibitors
-
Cyclooxygenase Inhibitors / pharmacology
-
Cyclooxygenase Inhibitors / therapeutic use
-
Drug Design
-
Eflornithine / pharmacology
-
Eflornithine / therapeutic use
-
Enzyme Inhibitors / pharmacology
-
Enzyme Inhibitors / therapeutic use
-
Forecasting
-
Genes, Tumor Suppressor
-
Humans
-
Isoenzymes / antagonists & inhibitors
-
Membrane Proteins
-
Models, Biological
-
Neoplasms / drug therapy
-
Neoplasms / genetics
-
Neoplasms / metabolism*
-
Neoplasms / prevention & control
-
Oncogenes
-
Ornithine Decarboxylase / genetics
-
Ornithine Decarboxylase / metabolism
-
Ornithine Decarboxylase Inhibitors
-
Polyamines / metabolism*
-
Prostaglandin-Endoperoxide Synthases
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Antineoplastic Agents
-
Cyclooxygenase 2 Inhibitors
-
Cyclooxygenase Inhibitors
-
Enzyme Inhibitors
-
Isoenzymes
-
Membrane Proteins
-
Ornithine Decarboxylase Inhibitors
-
Polyamines
-
Cyclooxygenase 2
-
PTGS2 protein, human
-
Prostaglandin-Endoperoxide Synthases
-
Ornithine Decarboxylase
-
Eflornithine